Inhaled drug delivery forms the basis of many respiratory disease treatment regimes. Dr. Nveed Chaudhary, chief scientific and regulatory officer at Broughton, shares how developments in inhaled drug delivery technology could both improve the treatment of these diseases, and enable the delivery of a wider range of active substances - from anaesthetics to generic drug delivery.
Key insights:
- Unlike a drug delivered via intravenous injection, inhaled drug delivery doesn't need to pass around the body before reaching its target and is therefore less likely to be metabolised.
- There is an increasing demand for aerosol and inhalation products to improve patient outcomes in the treatment of respiratory disease and other conditions.
- There are opportunities for developing generic drugs via inhalation, as well as corticosteroids and anaesthetics - with the intention of lowering dose and mitigating side effects.
For treatment of diseases of the lung, throat, and oesophagus, the most obvious advantage of inhalation therapy is target organ delivery. However, there are distinct advantages to delivering pharmaceuticals via inhalation therapy where target organ delivery is not the primary focus.